# A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

> **NCT07723118** · PHASE1 · COMPLETED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 10 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Adagrasib

## Key facts

- **NCT ID:** NCT07723118
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-08-05
- **Primary completion:** 2026-09-08
- **Final completion:** 2026-09-14
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723118, "A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07723118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*